278 related articles for article (PubMed ID: 26941130)
1. Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study.
Saraux A; Rouanet S; Flipo RM; Poncet JC; Fardellone P; Hilliquin P; Idier I; Cantagrel A
Clin Exp Rheumatol; 2016; 34(2):303-10. PubMed ID: 26941130
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice.
Fortunet C; Pers YM; Lambert J; Godfrin-Valnet M; Constant E; Devilliers H; Gaudin P; Jorgensen C; Prades BP; Wendling D; Maillefert JF
Rheumatology (Oxford); 2015 Apr; 54(4):672-7. PubMed ID: 25246640
[TBL] [Abstract][Full Text] [Related]
3. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors: a single-center retrospective cohort study (KEIO-TCZ study) at week 52.
Izumi K; Kaneko Y; Yasuoka H; Seta N; Kameda H; Kuwana M; Takeuchi T
Mod Rheumatol; 2015 Jan; 25(1):31-7. PubMed ID: 24684408
[TBL] [Abstract][Full Text] [Related]
5. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab efficacy and safety in rheumatoid arthritis patients after inadequate response to disease-modifying anti-rheumatic drugs oranti-tumor necrosis factor.
Abdulkader OAF; Qushmaq K; Aljishi F
Ann Saudi Med; 2016; 36(3):190-6. PubMed ID: 27236390
[TBL] [Abstract][Full Text] [Related]
7. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study.
Caporali R; Idolazzi L; Bombardieri S; Ferraccioli G; Gerli R; Govoni M; Matucci Cerinic M; Pomponio G; Salaffi F; Tirri R; Benaglio F; Bianchino L; Sarzi-Puttini P;
Clin Exp Rheumatol; 2017; 35(6):919-928. PubMed ID: 28516890
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
Sagawa A
Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
[TBL] [Abstract][Full Text] [Related]
9. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
[TBL] [Abstract][Full Text] [Related]
10. [Relationship of the clinical efficiency of tocilizumab therapy to the serum level of matrix metalloproteinase-3 in patients with rheumatoid arthritis].
Avdeeva AS; Aleksandrova EN; Novikov AA; Cherkasova MV; Panasyuk EY; Nasonov EL
Ter Arkh; 2013; 85(5):24-9. PubMed ID: 23819335
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice.
Narváez J; Magallares B; Díaz Torné C; Hernández MV; Reina D; Corominas H; Sanmartí R; LLobet JM; Rodriguez de la Serna A; Nolla JM
Semin Arthritis Rheum; 2016 Feb; 45(4):386-90. PubMed ID: 26254548
[TBL] [Abstract][Full Text] [Related]
12. Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice.
Notario Ferreira I; Ferrer González MA; Morales Garrido P; González Utrilla A; García Sanchez A; Soto Pino MJ; Suero Rosario E; Caro Hernández C; Añón Oñate I; Pérez Albaladejo L; Cáliz Cáliz R
Reumatol Clin; 2017; 13(2):78-84. PubMed ID: 27174398
[TBL] [Abstract][Full Text] [Related]
13. Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies.
Haraoui B; Casado G; Czirják L; Taylor A; Bernasconi C; Reiss W; Caporali R
Clin Exp Rheumatol; 2017; 35(6):899-906. PubMed ID: 28516886
[TBL] [Abstract][Full Text] [Related]
14. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
Daïen CI; Gailhac S; Audo R; Mura T; Hahne M; Combe B; Morel J
Rheumatology (Oxford); 2015 Apr; 54(4):601-8. PubMed ID: 25231180
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI.
Suzuki T; Horikoshi M; Sugihara M; Hirota T; Ogishima H; Umeda N; Kondo Y; Tsuboi H; Hayashi T; Chino Y; Matsumoto I; Sumida T
Mod Rheumatol; 2013 Jul; 23(4):782-7. PubMed ID: 22975733
[TBL] [Abstract][Full Text] [Related]
16. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.
Choy E; Caporali R; Xavier R; Fautrel B; Sanmarti R; Bao M; Devenport J; Pethö-Schramm A
Rheumatology (Oxford); 2019 Jun; 58(6):1056-1064. PubMed ID: 30649524
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of safety, efficacy and post-cessation efficacy durability of tocilizumab in patients with active rheumatoid arthritis.
Ahmadzadeh A; Farahmand AN; Gachkar L
Int J Rheum Dis; 2017 Feb; 20(2):231-237. PubMed ID: 26385018
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Prednisone Use in Patients with Rheumatoid Arthritis Initiating Treatment with Tocilizumab in Routine US Clinical Practice.
Pappas DA; Etzel CJ; Zlotnick S; Best J; Blachley T; Kremer JM
Rheumatol Ther; 2019 Sep; 6(3):421-433. PubMed ID: 31240499
[TBL] [Abstract][Full Text] [Related]
19. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.
Genovese MC; Rubbert-Roth A; Smolen JS; Kremer J; Khraishi M; Gómez-Reino J; Sebba A; Pilson R; Williams S; Van Vollenhoven R
J Rheumatol; 2013 Jun; 40(6):768-80. PubMed ID: 23457383
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan.
Koike T; Harigai M; Inokuma S; Ishiguro N; Ryu J; Takeuchi T; Takei S; Tanaka Y; Sano Y; Yaguramaki H; Yamanaka H
J Rheumatol; 2014 Jan; 41(1):15-23. PubMed ID: 24187110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
